Tags : Braftovi

The US FDA Approves New Indication for Lilly’s Erbitux (cetuximab)

Tuba Khan September 29, 2021

Shots: The approval is based on P-III BEACON CRC trial evaluating Braftovi (300mg, qd) + Erbitux vs irinotecan + Erbitux or Folfiri + Erbitux in a ratio (1:1:1) in 441 […]readmore

Pharma

Array Biopharma Reports Results of Triplet Combination Therapy in P-III

Vartika Singh January 15, 2019

Shots: The safety lead-in P-III BEACON CRC study involves assessing of a triplet combination Braftovi (encorafenib), Mektovi (binimetinib) & Erbitux (cetuximab) in patients with BRAF mutant mCRC P-III BEACON CRC […]readmore

Tags : Braftovi

The US FDA Approves New Indication for Lilly’s Erbitux (cetuximab)

Array Biopharma Reports Results of Triplet Combination Therapy in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Braftovi

The US FDA Approves New Indication for Lilly’s Erbitux (cetuximab)

Array Biopharma Reports Results of Triplet Combination Therapy in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company